SI2654736T1 - Novi farmacevtski sestavki - Google Patents

Novi farmacevtski sestavki

Info

Publication number
SI2654736T1
SI2654736T1 SI201131918T SI201131918T SI2654736T1 SI 2654736 T1 SI2654736 T1 SI 2654736T1 SI 201131918 T SI201131918 T SI 201131918T SI 201131918 T SI201131918 T SI 201131918T SI 2654736 T1 SI2654736 T1 SI 2654736T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical composition
novel pharmaceutical
novel
composition
pharmaceutical
Prior art date
Application number
SI201131918T
Other languages
English (en)
Slovenian (sl)
Inventor
Douglas J. Demarini
Ngocdiep T. Le
Francisco Henriquez
Lihong Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2654736(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2654736T1 publication Critical patent/SI2654736T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201131918T 2010-12-20 2011-12-20 Novi farmacevtski sestavki SI2654736T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20
EP11849974.8A EP2654736B1 (en) 2010-12-20 2011-12-20 Novel pharmaceutical composition
PCT/US2011/066021 WO2012088033A2 (en) 2010-12-20 2011-12-20 Novel pharmaceutical composition

Publications (1)

Publication Number Publication Date
SI2654736T1 true SI2654736T1 (sl) 2020-10-30

Family

ID=46314827

Family Applications (3)

Application Number Title Priority Date Filing Date
SI201132108T SI4159205T1 (sl) 2010-12-20 2011-12-20 Nov farmacevtski sestavek
SI201132109T SI4159204T1 (sl) 2010-12-20 2011-12-20 Nov farmacevtski sestavek
SI201131918T SI2654736T1 (sl) 2010-12-20 2011-12-20 Novi farmacevtski sestavki

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI201132108T SI4159205T1 (sl) 2010-12-20 2011-12-20 Nov farmacevtski sestavek
SI201132109T SI4159204T1 (sl) 2010-12-20 2011-12-20 Nov farmacevtski sestavek

Country Status (38)

Country Link
US (5) US20130266649A1 (enExample)
EP (4) EP2654736B1 (enExample)
JP (2) JP6126014B2 (enExample)
KR (1) KR101911109B1 (enExample)
CN (1) CN103998041B (enExample)
AR (2) AR084102A1 (enExample)
AU (1) AU2011349422B2 (enExample)
BR (1) BR112013015602B1 (enExample)
CA (1) CA2822701C (enExample)
CL (1) CL2013001779A1 (enExample)
CR (1) CR20130352A (enExample)
CY (1) CY1123376T1 (enExample)
DK (3) DK4159205T3 (enExample)
DO (1) DOP2013000138A (enExample)
EA (1) EA025198B1 (enExample)
ES (3) ES2985024T3 (enExample)
FI (2) FI4159205T3 (enExample)
HR (3) HRP20240563T1 (enExample)
HU (3) HUE066526T2 (enExample)
IL (1) IL226855A (enExample)
JO (1) JO3594B1 (enExample)
LT (3) LT4159204T (enExample)
MA (1) MA34883B1 (enExample)
MX (1) MX2013007073A (enExample)
MY (1) MY170501A (enExample)
NZ (1) NZ612157A (enExample)
PE (1) PE20140040A1 (enExample)
PH (1) PH12013501209A1 (enExample)
PL (3) PL4159205T3 (enExample)
PT (3) PT4159204T (enExample)
RS (2) RS65497B1 (enExample)
SG (1) SG191054A1 (enExample)
SI (3) SI4159205T1 (enExample)
TW (1) TWI505828B (enExample)
UA (1) UA113158C2 (enExample)
UY (1) UY33818A (enExample)
WO (1) WO2012088033A2 (enExample)
ZA (1) ZA201304189B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
BR112015003418A2 (pt) 2012-08-17 2017-07-04 Hoffmann La Roche produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica.
AU2013352369B2 (en) * 2012-11-30 2016-07-28 Novartis Ag. Novel pharmaceutical composition
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1(2H)-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
PL3496722T3 (pl) * 2016-08-10 2025-11-12 F. Hoffmann-La Roche Ag Kompozycje farmaceutyczne zawierające inhibitory kinazy białkowej Akt
RU2627692C1 (ru) 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
TW201818936A (zh) 2016-11-25 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種吡啶酮類衍生物醫藥組成物及其製備方法
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
CA3138123A1 (en) 2019-05-13 2020-11-19 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
JP2022540253A (ja) * 2019-07-11 2022-09-14 プラクシス プレシジョン メディシンズ, インコーポレイテッド T型カルシウムチャネル調節因子の製剤およびその使用方法
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
EP4444299A1 (en) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
RU2364596C2 (ru) * 2004-06-11 2009-08-20 Джапан Тобакко Инк. ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US7955622B2 (en) * 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
WO2008060890A2 (en) * 2006-11-09 2008-05-22 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
EP2175885B1 (en) * 2007-07-30 2016-10-12 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
US8414918B2 (en) * 2007-09-25 2013-04-09 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
KR20110031370A (ko) 2008-07-08 2011-03-25 베타 파마, 인크. 염산 icotinib, 합성, 결정형, 약학적 조성물 및 이의 사용
AU2010298280B2 (en) 2009-09-23 2014-07-03 Novartis Ag Combination
EA021951B1 (ru) 2009-09-23 2015-10-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Противораковая комбинация
EA201270475A1 (ru) 2009-09-28 2012-11-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинация
RS65800B1 (sr) * 2009-10-16 2024-08-30 Novartis Ag Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
EP2501379B1 (en) 2009-11-17 2016-03-23 Novartis AG Combination
US20130165456A1 (en) 2010-08-26 2013-06-27 Tona M. Gilmer Combination
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit
CZ2015278A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Krystalické formy trametinibu

Also Published As

Publication number Publication date
LT4159205T (lt) 2024-05-10
LT2654736T (lt) 2020-09-25
UY33818A (es) 2012-07-31
CN103998041A (zh) 2014-08-20
KR101911109B1 (ko) 2018-10-23
WO2012088033A3 (en) 2014-03-13
PT4159204T (pt) 2024-05-07
FI4159205T3 (fi) 2024-04-23
CN103998041B (zh) 2016-08-17
US8580304B2 (en) 2013-11-12
HRP20201409T1 (hr) 2020-11-27
BR112013015602A2 (pt) 2017-02-21
SG191054A1 (en) 2013-08-30
DK2654736T3 (da) 2020-09-14
EA201390913A1 (ru) 2014-04-30
HRP20240564T1 (hr) 2024-09-27
JO3594B1 (ar) 2020-07-05
BR112013015602B1 (pt) 2022-03-03
US9399021B2 (en) 2016-07-26
FI4159204T3 (fi) 2024-04-22
DK4159205T3 (da) 2024-05-13
IL226855A (en) 2017-04-30
TWI505828B (zh) 2015-11-01
DOP2013000138A (es) 2013-11-30
HUE050788T2 (hu) 2021-01-28
LT4159204T (lt) 2024-05-10
CA2822701C (en) 2018-10-23
US20120183613A1 (en) 2012-07-19
RS65497B1 (sr) 2024-06-28
HUE066526T2 (hu) 2024-08-28
HUE066525T2 (hu) 2024-08-28
EP4159205B1 (en) 2024-02-14
NZ612157A (en) 2015-05-29
US20140154316A1 (en) 2014-06-05
ES2982775T3 (es) 2024-10-17
ES2985024T3 (es) 2024-11-04
UA113158C2 (xx) 2016-12-26
EP2654736A4 (en) 2015-04-22
PT2654736T (pt) 2020-09-24
PL4159205T3 (pl) 2024-06-24
JP6126014B2 (ja) 2017-05-10
HRP20240563T1 (hr) 2024-08-16
CA2822701A1 (en) 2012-06-28
PE20140040A1 (es) 2014-02-26
MY170501A (en) 2019-08-08
WO2012088033A2 (en) 2012-06-28
SI4159204T1 (sl) 2024-06-28
EA025198B1 (ru) 2016-11-30
CL2013001779A1 (es) 2014-06-27
ZA201304189B (en) 2014-02-26
MA34883B1 (fr) 2014-02-01
US20140099365A1 (en) 2014-04-10
SI4159205T1 (sl) 2024-06-28
EP4159204B1 (en) 2024-02-14
AU2011349422B2 (en) 2015-12-10
EP4159205A1 (en) 2023-04-05
EP3808343A1 (en) 2021-04-21
PT4159205T (pt) 2024-05-08
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
KR20130130028A (ko) 2013-11-29
US9271941B2 (en) 2016-03-01
AU2011349422A1 (en) 2013-05-02
CY1123376T1 (el) 2021-12-31
US9155706B2 (en) 2015-10-13
US20130266649A1 (en) 2013-10-10
US20140037726A1 (en) 2014-02-06
ES2820536T3 (es) 2021-04-21
JP2014510704A (ja) 2014-05-01
PL2654736T3 (pl) 2020-12-14
CR20130352A (es) 2013-12-18
MX2013007073A (es) 2013-09-26
JP2017137299A (ja) 2017-08-10
EP2654736A2 (en) 2013-10-30
AR084102A1 (es) 2013-04-24
PL4159204T3 (pl) 2024-07-01
AR122185A2 (es) 2022-08-24
RS65496B1 (sr) 2024-06-28
PH12013501209A1 (en) 2013-07-29
EP4159204A1 (en) 2023-04-05
TW201249441A (en) 2012-12-16

Similar Documents

Publication Publication Date Title
IL245326A0 (en) pharmaceutical preparation
PT2619182T (pt) Composição farmacêutica
IL225457A0 (en) Pharmaceutical composition
ZA201304189B (en) Novel pharmaceutical composition
HUE031336T2 (hu) Gyógyszerészeti készítmények
PT2579858E (pt) Composição farmacêutica que contém ivabradina
ZA201301920B (en) Pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
SG10201508982TA (en) Pharmaceutical compositions
IL221501A (en) Medicinal product containing miramistine
EP2560678A4 (en) PHARMACEUTICAL COMPOSITIONS
GB201001911D0 (en) Pharmaceutical composition
GB201019775D0 (en) Pharmaceutical composition
HU1000006D0 (en) Improved pharmaceutical composition
GB201005403D0 (en) Novel pharmaceutical compositions
GB201008590D0 (en) Pharmaceutical compositions
SG10201509530YA (en) Pharmaceutical compositions